Evidence map›Paper›PMID 34991453›Full record

ArticleBMC bioinformatics2022

vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding.

Vi Ngoc-Nha Tran, Alireza Shams, Sinan Ascioglu, Antal Martinecz, Jingyi Liang, Fabrizio Clarelli, Rafal Mostowy, Ted Cohen, Pia Abel Zur Wiesch

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 65% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 5 countries.

Vi Ngoc-Nha TranDepartment of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, 9037, Tromsø, Norway. vi.tran@uit.no.ORCID http://orcid.org/0000-0002-7150-6434
Alireza ShamsPolytechnique Montréal, Montreal, QC, H3T 1J4, Canada.
Sinan AsciogluIntegrated Digital Media Department, New York University, New York, USA.
Antal MartineczDepartment of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, 9037, Tromsø, Norway.
Jingyi LiangDepartment of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, 9037, Tromsø, Norway.
Fabrizio ClarelliDepartment of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, 9037, Tromsø, Norway.
Rafal MostowyMalopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.
Ted CohenDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, USA.
Pia Abel Zur WieschDepartment of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, 9037, Tromsø, Norway.
UiT The Arctic University of Norway · NOPennsylvania State University · USJagiellonian University · PLNew York University · USPolytechnique Montréal · CAYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Bill and Melinda Gates Foundation OPP1111658JPI-EC-AMR 271176/H10NCATS NIH HHS UL1 TR001863Research Council of Norway (NFR) 262686
6 · The paper itself

Abstract

backgroundAs antibiotic resistance creates a significant global health threat, we need not only to accelerate the development of novel antibiotics but also to develop better treatment strategies using existing drugs to improve their efficacy and prevent the selection of further resistance. We require new tools to rationally design dosing regimens from data collected in early phases of antibiotic and dosing development. Mathematical models such as mechanistic pharmacodynamic drug-target binding explain mechanistic details of how the given drug concentration affects its targeted bacteria. However, there are no available tools in the literature that allow non-quantitative scientists to develop computational models to simulate antibiotic-target binding and its effects on bacteria.

resultsIn this work, we have devised an extension of a mechanistic binding-kinetic model to incorporate clinical drug concentration data. Based on the extended model, we develop a novel and interactive web-based tool that allows non-quantitative scientists to create and visualize their own computational models of bacterial antibiotic target-binding based on their considered drugs and bacteria. We also demonstrate how Rifampicin affects bacterial populations of Tuberculosis bacteria using our vCOMBAT tool.

conclusionsThe vCOMBAT online tool is publicly available at https://combat-bacteria.org/ .

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialBacteriaComputer SimulationModels, BiologicalAnti-Bacterial AgentsAntibioticBinding kineticsComputational modelPharmacodynamicsPharmacokineticsWeb-based tool

Identifiers

PMID34991453
PMCPMC8734216
OpenAlexW4225364091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.